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Background-—Fetuin-A may be involved in the etiology of coronary heart disease (CHD) through opposing pathways (ie, promoting
insulin resistance and inhibiting ectopic calciﬁcation). We aimed to explicitly examine whether systemic inﬂammation, a factor
leading to elevated vascular calciﬁcation, may modify the association between fetuin-A and CHD risk.
Method and Results-—During 16 years of follow-up (1990–2006), we prospectively identiﬁed and conﬁrmed 466 incident fatal or
nonfatal CHD case in the Nurses’ Health Study. For each case, 1 healthy control was selected using risk-set sampling from 26 245
eligible participants. Cases and controls were matched for age, smoking status, fasting status, and date of blood draw. After
multivariate adjustment for lifestyle factors, body mass index, diet, and blood lipids, fetuin-A levels were not associated with CHD
risk in the whole population: odds ratio (OR) (95% CI) comparing extreme quintiles of fetuin-A was 0.79 (0.44 to 1.40). However, a
signiﬁcant inverse association was observed among participants with higher C-reactive protein levels (Pinteraction=0.04). The OR
(95% CI) comparing highest versus lowest quintiles of fetuin-A was 0.50 (0.26 to 0.97; Ptrend=0.004) when C-reactive protein levels
were above population median (0.20 mg/dL), whereas among the remainder of the participants, the corresponding OR (95% CI)
was 1.09 (0.58 to 2.05; Ptrend=0.75).
Conclusions-—In this population of US women, fetuin-A levels were associated with lower CHD risk when C-reactive protein levels
were high, but null association was observed among participants with lower C-reactive protein levels. This divergent pattern of
association needs replication in future studies. (J Am Heart Assoc. 2014;3:e000939 doi: 10.1161/JAHA.114.000939)
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A
ccumulating evidence has suggested the role of ectopic
vascular calciﬁcation in the etiology of cardiovascular
disease (CVD) through increased aortic rigidity, impaired
stability of atherosclerotic plaque, and valve dysfunction.
1
Observational human studies have consistently documented a
clear association between vascular calciﬁcation and risk of
CVD or mortality,
2 and such an association is particularly
strong among patients with chronic kidney disease (CKD) or
diabetes,
2,3 who typically suffer the most severe vascular
calciﬁcation. Under physiological conditions, calcium precip-
itation in the vascular system is a tightly regulated process
that involves multiple factors to prevent lethal vascular
calciﬁcation.
4 Of these factors, fetuin-A (ie, a2-HS-glycopro-
tein) has been identiﬁed as the primary inhibitor of tissue
calciﬁcation and may account for half of the capacity to inhibit
salt precipitation in circulation.
5,6 In line with this function,
higher fetuin-A concentrations were consistently associated
with less severe vascular calciﬁcation,
7–9 better survival,
10,11
and lower CVD incidence or death
11–14 among CKD patients.
However, thus far, 3 prospective studies conducted among
healthy people generated mixed results regarding fetuin-A
levels in relation to CVD risk.
15–17
The inconsistent ﬁndings observed in general populations
versus CKD patients may be explained by the diverse functions
offetuin-A.Inadditiontoinhibitingcalciumprecipitation,fetuin-
A inhibits the insulin receptor and results in impaired insulin
sensitivity
18,19 and an elevated diabetes risk.
20–23 The associ-
ations between fetuin-A levels and CVD risk may thus depend
on the baseline risk proﬁles of study participants that may
amplify fetuin-A’s effects through one pathway over the other.
This notion has been supported by evidence from recent
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15,16 In the current analysis, we
extended this line of research by evaluating the associations
between fetuin-A levels and coronary heart disease (CHD) and
explicitly examining whether inﬂammation, a process closely
involved in ectopic vascular calciﬁcation,
1 modiﬁes the asso-
ciations of interest among generally healthy US women in the
Nurses’ Health Study (NHS).
Methods
Study Population
The NHS is an ongoing prospective study consisting of
121 700 female registered nurses aged 30 to 55 years who
were enrolled in 1976 and have been continuously followed
through biennial questionnaires.
24 In 1989–1990, 32 826
NHS participants provided blood samples that were sent via
an overnight courier to a central biorepository, and the
majority (97%) of the samples arrived within 26 hours of blood
draw. On arrival, these samples were centrifuged and
aliquoted into cryotubes as plasma, buffy coat, and erythro-
cytes, and they were then stored in the vapor phase of liquid
nitrogen freezers at a temperature ≤130°C until analysis.
Among these participants who provided blood samples, a high
response rate (>94%) has been maintained.
Ascertainment of CHD
On the baseline and all biennial follow-up questionnaires,
participants are queried about the occurrence of physician-
diagnosed CHD events and other diseases. We then request
permission to access medical records of those who report
having a nonfatal myocardial infarction (MI). Exposure-blinded
study physicians review all medical records and conﬁrm or
refute the self-reports of nonfatal MI using the World Health
Organization criteria, which require typical symptoms plus
either diagnostic electrocardiographic ﬁndings or elevated
cardiacenzymelevels.
25Deathswereidentiﬁedbyreportsfrom
next of kin or postal authorities or by searching the National
Death Index. At least 98% of deaths among the NHS partici-
pants were identiﬁed using these approaches.
26 We identify
fatalCHDcasesifCHDislistedasthecauseofdeathinautopsy
reports,hospitalrecords,ordeathcertiﬁcates,andthesecases
are conﬁrmed if there is a previous report of CHD and no other
more plausible cause of death. Unconﬁrmed CHD deaths were
excluded from the present study. In the current analysis, we
included both nonfatal MI and fatal CHD cases.
Prospective Case-Control Study Design
Among 26 245 participants who provided blood samples and
were free of cancer and CVD at blood collection, 466 incident
cases of nonfatal MI and fatal CHD were identiﬁed and
conﬁrmed from the date of blood draw through June 2006. A
risk-set sampling scheme was used to randomly select 1
control for each case from the rest of the population who
remained free of CHD events when the CHD case occurred. We
matched cases and controls for age at blood draw (1 year)
and smoking status (never, past, and current) to control for
confounding. In addition, fasting status at blood draw (fasting
for 10 hours or not) and date of blood draw were matched to
minimize extraneous variation in biomarker distribution
between cases and controls. Of note, to preserve statistical
power,wealsoincluded6additionalcontrolsmatchedtocases
whose diagnoses were initially conﬁrmed by participants
themselves through telephone interview or letter correspon-
dence but were later disconﬁrmed by medical record review.
The study protocol was approved by the institutional
review board of the Brigham and Women’s Hospital and the
Human Subjects Committee Review Board of Harvard School
of Public Health.
Measurement of Plasma Levels of Fetuin-A and
Other Biomarkers
Samples of the case-control pairs were shipped in the same
batch and analyzed in the same run. Within each batch,
samples of each pair were assayed by the same technicians in
a random sequence under identical conditions to minimize
systematic biases. Fetuin-A levels were measured by an
enzyme immunoassay (EIA) from R & D Systems (Minneapolis,
MN).
22 In addition, plasma levels of total cholesterol (TC),
high-density lipoprotein cholesterol (HDL-C), and low-density
lipoprotein cholesterol (LDL-C), fasting triacylglycerol (TG),
high-sensitivity C-reactive protein (hsCRP), total adiponectin,
and creatinine, as well as erythrocyte hemoglobin A1c (HbA1c)
levels, were also measured among the study participants. In a
smaller sample (total n=387~404), plasma levels of
interleukin-6 (IL-6) and tumor necrosis factor receptor (TNF-
R) 1 and 2 were also measured. Details of the methodology of
these assays were published elsewhere.
27–29 Quality control
samples (n=84) were run along with the case-control
samples. Based on the measurements of these samples, the
average intra-assay coefﬁcient of variation (CV) was 11.8% for
fetuin-A. The CVs were 3.9% for hsCRP, 10.6% for creatinine,
5.0% for TC, 4.7% for HDL-C, 4.9% for LDL-C, 6.2% for TG,
10.3% for total adiponectin, 0.8% for HbA1c, 21.8% for IL-6,
and 9.2% for TNF-R1 and TNF-R2.
Assessment of Covariates
In the NHS questionnaires, information on medical history,
lifestyle, body weight and height, family history of MI,
menopausal status, and postmenopausal hormone use has
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calculated body mass index (BMI) as weight divided by height
squared (kg/m
2). Diet has been assessed using a validated
semiquantitative food frequency questionnaire
30 every 2 to
4 years since 1980. Covariates assessed using the 1990
questionnaire were considered in the analysis as the majority
of our participants provided blood samples in 1989–1990. To
represent long-term diet, cumulative averages of dietary
variables were calculated through 1990.
31 The estimated
glomerular ﬁltration rate (eGFR) was calculated using the
Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI)
equation.
32 An eGFR <60 mL/min per 1.73 m
2 was used to
deﬁne kidney dysfunction.
Statistical Analysis
Associations of plasma fetuin-A levels with blood lipids,
inﬂammatory markers, and other CHD risk markers were
evaluated using generalized linear regression to calculate
least-squares means of the biomarkers by quintiles of fetuin-A
levels among controls. The least-squares means were
adjusted for age at blood draw, BMI, smoking status,
postmenopausal status and hormone use, alcohol use, and
fasting status.
The study population was categorized into quintiles
according to the distribution of fetuin-A levels among controls
for the examination of the association between fetuin-A and
CHD risk using conditional logistic regression.
33 In multivar-
iate analysis, we controlled for all matching factors, as well as
established anthropometric (ie, BMI), lifestyle (ie, physical
activity and use of aspirin), dietary (ie, alcohol use and
alternative Healthy Eating Index score [summarizing higher
intakes of vegetables, fruit, nuts, soy, and cereal ﬁber, higher
ratios of chicken plus ﬁsh to red meat and polyunsaturated to
saturated fat, lower intake of trans fat, and multivitamin use
of ≥5 years]
34), or clinical (ie, postmenopausal status and
hormone use, parental history of MI before age 65 years,
history of hypercholesterolemia, hypertension, or diabetes,
and total:HDL-C ratio) risk factors of CHD. We estimated P
values for linear trend by modeling log-transformed fetuin-A
levels in the multivariate models. We also evaluated the linear
relationship by modeling the associations for each 1-SD
increment of log-transformed fetuin-A levels. Furthermore, we
used Rosner et al’s method to correct for random measure-
ment error,
35 the extent of which was measured by within-
person stability of fetuin-A levels (an intraclass correlation of
0.88 of fetuin-A levels was estimated between samples
collected 1 to 2 years apart).
22
To examine interactions between fetuin-A levels and other
variables, we ﬁrst constructed an interaction term between
log-transformed fetuin-A levels (lg/mL) and the interacting
variable (eg, high versus low hsCRP levels) at issue and then
modeled the signiﬁcance of the interaction term using
conditional logistic regression. We used unconditional logistic
regression in stratiﬁed analyses to preserve statistical power
as much as possible since matched cases and controls were
not necessarily in the same strata. To model the dose–
response relationship, we used restricted cubic spline
regressions with 3 knots to examine possible nonlinear
relationships between fetuin-A levels and CHD risk. Tests for
nonlinearity were based on the likelihood ratio test, compar-
ing the model with only the linear term to the model with the
linear and the cubic spline terms. To minimize the impact of
outliers, we excluded participants in the highest and lowest
1% of fetuin-A levels.
All P values were 2-sided, and 95% CIs were calculated for
ORs. Data were analyzed with use of the Statistical Analysis
Systems software package, version 9.3 (SAS Institute).
Results
Demographic and lifestyle characteristics assessed at blood
draw are shown in Table 1. The matching factors had similar
distributions between cases and controls. As expected, cases
otherwise had generally high-risk proﬁles than did controls.
For example, cases had higher BMI, lower alcohol intake, and
higher probability of having a history of cardiometabolic
diseases or family history of MI than did controls. In terms of
the distribution of CHD risk markers, cases and controls had
similar levels of fetuin-A and TC, although levels of other lipid
parameters, hsCRP, HbA1c, and total adiponectin, were
different between the 2 groups. Among controls, fetuin-A
levels were signiﬁcantly associated with the levels of total:
HDL-C ratio and TG (Table 2) and were associated with lower
total adiponectin levels with borderline signiﬁcance. Of note,
there was no clear association between fetuin-A levels and
eGFR among the controls.
Table 3 presents the associations between quintiles of
fetuin-A levels and risk of developing CHD. In a crude model in
which matching factors were adjusted, fetuin-A levels were
associated with a nonsigniﬁcant, increased risk of CHD.
Further adjustment for BMI, lifestyle factors, medical history,
diet, and total:HDL-C ratio reversed this association, although
none of the ORs of the quintiles reached statistical signif-
icance. In secondary analyses, additional adjustment for
eGFR, TG, hsCRP, or total adiponectin did not change the
association (Model 4), although the 95% CIs were wider
because of decreased sample size.
We explicitly evaluated the potential interaction between
hsCRP, a biomarker of systematic inﬂammation, and fetuin-A
levels on the associations with CHD. Among participants who
had higher hsCRP levels (hsCRP ≥0.20 mg/dL, the population
median), fetuin-A levels were signiﬁcantly associated with a
DOI: 10.1161/JAHA.114.000939 Journal of the American Heart Association 3
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observed a nonsigniﬁcant positive association among
participants with lower hsCRP levels (Pinteraction=0.04). Com-
paring extreme quintiles of fetuin-A levels, the ORs (95% CIs)
were 0.50 (0.26 to 0.97; Ptrend=0.004) when hsCRP levels
were high and 1.09 (0.58 to 2.05; Ptrend=0.75) otherwise.
When we used a higher hsCRP cut-off point (≥0.50 mg/dL;
22.3% of total population) to categorize participants, we
observed a similar pattern of associations, although neither
these associations nor the test for interaction reached
signiﬁcance level primarily because of diminished power:
the corresponding ORs (95% CIs) were 0.41 (0.14 to 1.19)
and 0.91 (0.55 to 1.52). Consistently, in spline regression
analysis, we observed a monotonic, inverse association
between fetuin-A levels and CHD risk among participants
with high CRP levels (Plinearity=0.04 and Pcurvature=0.56) but
not among the rest of participants (Figure 2). We further
estimated that for each 1-SD increment of log-transformed
Table 1. Baseline Characteristics of Coronary Heart Disease Patients and Controls in 1989–1990, the Nurses’ Health Study
Characteristics* Cases (N=466) Controls (N=470) P Value
†
Age, y
‡ 59.56.6 59.46.6 0.88
Body mass index, kg/m
2 26.45.2 25.24.3 0.0001
Physical activity, MET-h/wk 16.817.8 18.117.1 0.29
Alternate Healthy Eating Index score 37.88.1 38.48.7 0.31
Alcohol, g/day 5.58.8 6.89.7 0.03
Smoking status, %
‡ 0.85
Current smoker 25.3 24.1
Former smoker 37.8 38.3
Never smoked 36.9 37.7
Medical history
Diabetes, % 13.7 5.1 <0.0001
Hypertension, % 48.3 26.2 <0.0001
Hypercholesterolemia, % 53.2 40.6 0.0001
Parental MI before age 65 years, % 32.2 19.6 <0.0001
Fasting status, %
‡ 70.6 70.4 0.95
Postmenopausal status, % 0.52
Pre-menopause 11.2 13.2
Post-menopause, current hormone users 35.8 38.5
Post-menopause, past hormone users 18.2 16.4
Post-menopause, never used hormone 34.8 31.9
Use of aspirin, % 60.5 63.8 0.30
Biomarkers
§
Fetuin-A, lg/mL 457.0108.3 455.4119.4 0.83
TC, mg/dL 232.841.8 228.242.8 0.10
LDL-C, mg/dL 143.738.4 137.639.3 0.02
HDL-C, mg/dL 52.915.2 59.416.5 <0.0001
TG, mg/dL 142.584.7 118.562.9 <0.0001
hsCRP, mg/dL 0.480.77 0.300.44 <0.0001
HbA1c, % 5.91.4 5.50.6 <0.0001
Adiponectin, lg/mL 8.14.0 9.23.8 <0.0001
HbA1c indicates hemoglobin A1c; HDL-C, high-density lipoprotein cholesterol; hsCRP, high-sensitivity C-reactive protein; LDL-C, low-density lipoprotein cholesterol; MET-hr, metabolic
equivalent-hours; MI, myocardial infarction; TC, total cholesterol; TG, triacylglycerol.
*Plus-minus values are meanstandard deviation. Percentages are based on nonmissing data.
†P value estimates are based on Student t test for variables expressed as meanstandard deviation or Pearson v
2 test for variables expressed as percentages.
‡Matching factors.
§Data of hsCRP were missing for 20 participants, and this ﬁgure was 12 for TC and HDL-C, 22 for LDL-C, 60 for fasting TG, 14 for adiponectin, and 146 for HbA1c.
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to 43%) among participants with high hsCRP levels. After
correction for random measurement error, this reduction of
CHD risk was strengthened to 34% (95% CI 12% to 51%).
Using existing data on several other inﬂammatory markers,
including IL-6, TNF-R1, and TNF-R2, that were measured
among a subset of the study participants, we explored
interactions between fetuin-A levels and these inﬂammatory
markers (Figure 3). In general, we observed inverse associ-
ations of fetuin-A levels when levels of these inﬂammatory
markers were higher than the median: the ORs (95% CIs)
comparing extreme quintiles of fetuin-A were 0.49 (0.13 to
Table 2. Least-Squares Means* (Standard Error) of Cardiovascular Risk Markers by Levels of Fetuin-A Among Controls,
† the
Nurses’ Health Study
Quintiles of Fetuin-A (lg/mL)
P for
Trend 1 (Lowest) 2 3 4 5 (Highest)
Median, range 326.1 (83.0 to
368.6)
398.8 (369.0 to
423.2)
448.4 (425.1 to
472.0)
494.4 (472.2 to
536.3)
590.3 (536.8 to
1589.7)
Biomarkers
TC, mg/dL 222.8 (4.4) 234.9 (4.5) 226.2 (4.4) 227.0 (4.4) 230.1 (4.4) 0.55
LDL-C, mg/dL 133.3 (4.0) 145.9 (4.1) 136.7 (4.0) 135.3 (4.0) 137.3 (4.0) 0.96
HDL-C, mg/dL 60.4 (1.6) 59.3 (1.6) 59.6 (1.6) 60.8 (1.6) 56.7 (1.6) 0.19
Total:HDL-C ratio 3.9 (0.1) 4.3 (0.1) 4.0 (0.1) 4.0 (0.1) 4.4 (0.1) 0.02
TG mg/dL 111.5 (6.2) 112.7 (6.3) 110.0 (6.2) 115.1 (6.3) 144.7 (6.5) 0.0004
hsCRP, mg/dL 0.29 (0.04) 0.24 (0.04) 0.30 (0.04) 0.34 (0.04) 0.35 (0.04) 0.19
HbA1c, % 5.5 (0.1) 5.4 (0.1) 5.6 (0.1) 5.3 (0.1) 5.6 (0.1) 0.47
Adiponectin, lg/mL 9.8 (0.4) 9.2 (0.4) 9.4 (0.4) 9.2 (0.4) 8.7 (0.4) 0.06
eGFR, mL/min per
1.73 m
2
86.9 (1.5) 83.7 (1.5) 84.1 (1.5) 82.3 (1.5) 83.9 (1.5) 0.16
eGFR indicates estimated glomerular ﬁltration rate; HbA1c, hemoglobin A1c; HDL-C, high-density lipoprotein cholesterol; hsCRP, high-sensitivity C-reactive protein; LDL-C, low-density
lipoprotein cholesterol; TC, total cholesterol; TG, triacylglycerol.
*Adjusted for age at blood draw (year), body mass index (kg/m
2), smoking status (current smoker, past smoker, nonsmoker), postmenopausal status (yes, no), hormone use (current user,
past user, and nonuser), alcohol use (nondrinker, <5.0, 5.0 to 14.9, 15.0 to 29.9, and ≥30.0 g/day), and fasting status (yes, no).
†N=463 for TC, HDL-C, TC:HDL-C ratio, and eGFR, n=459 for LDL-C and hsCRP, n=439 for TG, n=461 for adiponectin, and n=396 for HbA1c.
Table 3. Relative Risk (95% CI) of Coronary Heart Disease by Levels of Fetuin-A, the Nurses’ Health Study
Quintiles of Biomarker Levels
P for Trend 1 (Lowest) 2 3 4 5 (Highest)
Fetuin-A, lg/mL
Median,
range
322.5 (83.0 to 369.0) 397.7 (369.0 to 424.3) 448.9 (425.1 to 472.0) 496.4 (472.2 to 536.7) 590.4 (536.8 to 1589.7)
Case-control 95/94 87/94 77/94 100/94 107/94
Model 1* 1.0 0.94 (0.60 to 1.47) 0.82 (0.51 to 1.31) 1.08 (0.69 to 1.70) 1.22 (0.76 to 1.97) 0.59
Model 2
† 1.0 0.74 (0.44 to 1.24) 0.69 (0.40 to 1.19) 0.82 (0.48 to 1.39) 0.95 (0.54 to 1.66) 0.64
Model 3
‡ 1.0 0.69 (0.41 to 1.17) 0.61 (0.35 to 1.06) 0.76 (0.44 to 1.30) 0.79 (0.44 to 1.40) 0.34
Model 4
§ 1.0 0.72 (0.41 to 1.25) 0.65 (0.36 to 1.18) 0.78 (0.44 to 1.39) 0.78 (0.42 to 1.45) 0.43
eGFR indicates estimated glomerular ﬁltration rate; HDL-C, high-density lipoprotein cholesterol; MET-hr, metabolic equivalent-hours; MI, myocardial infarction.
*Model 1 was adjusted for the matching factors, including age at blood draw, smoking status (never, past, current), fasting status (yes, no), and time of blood drawing.
†Based on model 1, model 2 was further adjusted for body mass index (kg/m
2), postmenopausal status (yes, no), hormone use (current user, past user, and nonuser), physical activity
(METs-h/wk; in tertiles), alcohol use (nondrinker, <5.0, 5.0 to 14.9, 15.0 to 29.9, and ≥30.0 g/day), parental history of MI before age 65 years (yes, no), history of hypercholesterolemia,
hypertension, or diabetes (yes, no), use of aspirin (yes, no), and alternate Healthy Eating Index score.
‡Based on model 2, model 3 was further adjusted for levels of total:HDL-C ratio.
§Based on model 3, model 4 was further adjusted for levels of fasting triacylglycerol (mg/dL), high-sensitivity C-reactive protein (mg/L), eGFR (mL/min per 1.73 m
2), and total adiponectin
(lg/mL).
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to 1.89) for TNF-R2. We further deﬁned an elevated-inﬂam-
mation status as the levels of all 4 inﬂammatory markers
(hsCRP, IL-6, TNF-R1, and TNF-R2) were above their medians,
and we examined the interaction by this inﬂammation status.
In this underpowered analysis (n=379), we observed a
nonsigniﬁcant interaction (Pinteraction=0.15): among partici-
pants with elevated levels of all inﬂammatory markers, the OR
(95% CI) was 0.35 (0.14 to 0.89) for each 1-SD increment of
log-transformed fetuin-A levels, whereas among the rest of
participants, the corresponding ﬁgures were 1.14 (0.83 to
1.58). The measurement error–corrected ORs (95% CIs) were
0.16 (0.03 to 0.87) and 1.20 (0.77 to 1.88), respectively.
Given the interactions between fetuin-A levels and existing
diabetes status observed in previous studies,
15,16 we also
evaluated potential effect modiﬁcations by diabetes status,
HbA1c levels, and adiposity on the associations of interest
(Figure 4). We did not ﬁnd any interaction by these risk
factors; the P values for interaction were 0.94, 0.24, and 0.10,
respectively. We did not observe any signiﬁcant interaction by
the presence of kidney dysfunction (eGFR <60 mL/min per
1.73 m
2), although among participants with impaired kidney
function (6.5% of total population), fetuin-A levels were
nonsigniﬁcantly associated with a lower CHD risk (Figure 5).
Discussion
In this largely healthy population of US women, baseline
plasma fetuin-A levels were not associated with the risk of
developing CHD during 16 years of follow-up. However, this
association may depend on the status of chronic systematic
inﬂammation in that fetuin-A levels were associated with
lower CHD risk among women with high CRP levels, whereas
among the remainder of the women, no association was
observed. A similar interaction by inﬂammation was observed
when we combined the data on other inﬂammatory markers
to deﬁne an elevated inﬂammatory status. These observations
were independent of established risk factors for CHD,
including BMI, lifestyle, diet, and blood lipids.
In comparison to evidence suggesting robust, favorable
associations between fetuin-A levels and CVD outcomes
among CKD patients,
10–14 results from prospective studies
conducted among general populations are inconsistent.
15–17
In the ﬁrst prospective investigation, Weikert et al found a
positive association between fetuin-A levels and risk of
developing MI and stroke in the EPIC-Potsdam study.
17 The
positive association persisted among subgroups of study
participants categorized by various baseline characteristics,
including diabetes status and CRP levels. In contrast, in the
other 2 prospective cohort studies conducted among general
populations, fetuin-A levels were associated with a lower CVD
incidence or mortality among nondiabetic participants, but the
opposite was observed among diabetic patients.
15,16 The
current study of CHD risk contributes to this complexity of
existing evidence by demonstrating a novel interaction by
inﬂammatory markers. These heterogeneous ﬁndings may be
potentially explained by the fact that a spectrum of CVD
outcomes was considered in the prior studies, which may
have distinct etiology with various relevance to fetuin-A’s
biology. Of note, in the NHS, plasma fetuin-A levels were not
associated with incident ischemic stroke risk.
36 Other sources
of heterogeneity may include the differential distribution of
sex, age, prevalence of existing diseases, and other factors
that determine the background CHD risk proﬁles of study
participants. Moreover, in these studies fetuin-A levels were
measured using various immunoassays with different sensi-
tivity and speciﬁcity in measuring the true fetuin-A levels,
37
and none of these studies, including ours, were able to
distinguish bound and free fetuin-A in the circulation.
38 On the
other hand, evidence regarding associations between fetuin-A
levels and incident diabetes risk is remarkably consistent
despite the different assays used in the studies.
20–23 Future
studies are warranted to further explore the sources of the
heterogeneity speciﬁc to the associations of fetuin-A with
CVD outcomes.
The ﬁndings regarding effect modiﬁcation by inﬂammatory
markers are supported by evidence from animal experiments
and human studies. Two functions of fetuin-A have been
extensively examined and consistently demonstrated in
animal models: fetuin-A inhibits both calcium precipitation
and insulin receptors’ activity at the tyrosine kinase
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Figure 1. Odds ratio (95% CI) of coronary heart disease for
plasma fetuin-A levels by high-sensitivity C-reactive protein
concentrations. Multivariate logistic regression models were
adjusted for the same set of covariates for model 3 in Table 3,
as well as matching factors. P for interaction=0.04.
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Figure 2. Dose-response relationship between fetuin-A levels and CHD risk stratiﬁed by plasma hsCRP
levels. Study participants with the lowest and highest 1% of fetuin-A were excluded to minimize potential
impact of outliers. Multivariate logistic regression models were adjusted for the same set of covariates for
model 3 in Table 3, as well as matching factors. Solid lines are ORs and dashed lines are 95% CIs. The
horizontal line is the reference line, and the dotted vertical lines are cut-off points for making quintiles.
A, hsCRP levels below median (0.20 mg/dL); (B) hsCRP levels above median. CHD indicates coronary
heart disease; hsCRP, high-sensitivity C-reactive protein; ORs, odds ratio.
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5,6,18,19 While fetuin-A’s detrimental effects on insulin
sensitivity might dictate and explain the robust associations
with type 2 diabetes, its dual functions may compete with
each other in determining the net effects on CVD in a speciﬁc
population. For example, in CKD patients who develop severe
intravascular calciﬁcation and have substantially increased
risk of CVD,
2 the effect of fetuin-A on inhibiting ectopic
calciﬁcation may outweigh the effect on impairing insulin
resistance, leading to an inverse association with CVD
mortality. In the general population, subclinical coronary
artery calciﬁcation can be detected among more than half of
middle-aged or older asymptomatic people.
9,39 While inﬂam-
mation has been established as a key promoter of vascular
calciﬁcation,
40,41 the association between inﬂammatory
markers and vascular calciﬁcation is somewhat inconclusive
in general population.
42 Meanwhile, in a recent prospective
investigation, a composite score of inﬂammation constituted
of multiple inﬂammatory markers was strongly associated
with the progression of coronary artery calciﬁcation.
43
Nonetheless, it is likely that among people with the procal-
ciﬁcation inﬂammatory status, fetuin-A’s beneﬁcial effects on
inhibiting ectopic calciﬁcation are more pronounced. This
notion is supported by a similar interaction by CRP levels on
the associations of fetuin-A with mortality among dialysis
patients.
44,45
The current study has several limitations that deserve
discussion. First, although the homogeneity in sex, ethnicity,
and profession of our study participants facilitates control of
confounding, the generalizability of the results is also limited
by these factors. Second, we did not correct for multiple
comparisons for testing a priori hypothesis. We cannot
exclude the possibility that the ﬁndings, especially the effect
modiﬁcation by inﬂammatory markers, are due to chance.
While further research is needed to replicate this observation,
this interaction is biologically plausible. In addition, we found
a stronger, inverse association of fetuin-A when other
inﬂammatory markers were also elevated. Third, data on
vascular calciﬁcation status are not available in the current
investigation. Therefore, we are unable to explore the inter-
relationships among inﬂammation markers, vascular calciﬁ-
cation, fetuin-A, and CHD risk. Fourth, although we controlled
for an array of CHD risk factors, we cannot exclude the role of
residual or unmeasured confounding in the observed associ-
ations. Fifth, random measurement errors as reﬂected by the
relatively high CV% of fetuin-A assay in comparison to other
studies might attenuate the true associations of interest. Last,
although we measured fetuin-A levels at only one time-point,
the high within-person stability of fetuin-A levels within 1 to
3 years suggests that a single measurement may reasonably
reﬂect levels of fetuin-A within a few years. Moreover, a
stability ICC of 0.52
36 was found between fetuin-A levels in
blood samples collected 10 years apart, further corroborating
the relatively small variation of fetuin-A levels over time.
In summary, among largely healthy US women, higher
plasma fetuin-A levels were associated with a lower risk of
developing CHD when systematic inﬂammation levels were
high, whereas no association was observed between fetuin-A
levels and CHD risk for participants with lower inﬂammation
levels. Although the current study provides new, biologically
plausible evidence linking fetuin-A and inﬂammation with CHD
risk, future studies are needed to replicate the ﬁndings and to
evaluate the clinical signiﬁcance of these ﬁndings in CHD risk
prediction.
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